-
1
-
-
10244247679
-
Underdetection of clinical benign prostatic hyperplasia in a general medical practice
-
Collins MF, Friedman RH, Ash A, Hall R, Moskowitz MA. Underdetection of clinical benign prostatic hyperplasia in a general medical practice. J Gen Intern Med 1996;11:513-8.
-
(1996)
J Gen Intern Med
, vol.11
, pp. 513-518
-
-
Collins, M.F.1
Friedman, R.H.2
Ash, A.3
Hall, R.4
Moskowitz, M.A.5
-
2
-
-
0026841280
-
Quantifying the smooth muscle content of the prostate using double-immuno-enzymatic staining and color assisted image analysis
-
Shapiro E, Hartanto V, Lepor H. Quantifying the smooth muscle content of the prostate using double-immuno-enzymatic staining and color assisted image analysis. J Urol 1992;147:1167-70.
-
(1992)
J Urol
, vol.147
, pp. 1167-1170
-
-
Shapiro, E.1
Hartanto, V.2
Lepor, H.3
-
3
-
-
29244467960
-
Managing patients with lower urinary tract symptoms
-
DOI 10.1016/j.amjmed.2004.12.033
-
McNaughton-Collins M, Barry MJ. Managing patients with lower urinary tract symptoms. Am J Med 2005;118:1331-9. DOI 10.1016/j.amjmed.2004.12.033
-
(2005)
Am J Med
, vol.118
, pp. 1331-1339
-
-
McNaughton-Collins, M.1
Barry, M.J.2
-
4
-
-
0034692176
-
Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH)
-
DOI 10.1021/jm990567u
-
Meyer MD, Alteabach RJ, Basha FZ, et al. Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH). J Med Chem 2000; 43:1586-603. DOI 10.1021/jm990567u
-
(2000)
J Med Chem
, vol.43
, pp. 1586-1603
-
-
Meyer, M.D.1
Alteabach, R.J.2
Basha, F.Z.3
-
5
-
-
0029779304
-
Evaluation of the pharmacological selectivity profile of alpha-1-adrenoceptor antagonists at prostatic alpha-1-adrenoceptors: Binding, functional and in vivo studies
-
Kenny BA, Miller AM, Williamson IJ, et al. Evaluation of the pharmacological selectivity profile of alpha-1-adrenoceptor antagonists at prostatic alpha-1-adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 1996;118:871-8.
-
(1996)
Br J Pharmacol
, vol.118
, pp. 871-878
-
-
Kenny, B.A.1
Miller, A.M.2
Williamson, I.J.3
-
6
-
-
0030974958
-
Effects of tamsulosin metabolites at alpha-1-adrenoceptors subtypes
-
Taguchi K, Saitoh M, Sato S, et al. Effects of tamsulosin metabolites at alpha-1-adrenoceptors subtypes. J Pharmacol Exp Ther 1997;280:1-5.
-
(1997)
J Pharmacol Exp Ther
, vol.280
, pp. 1-5
-
-
Taguchi, K.1
Saitoh, M.2
Sato, S.3
-
7
-
-
0029155804
-
KMD -3213, a novel, potent, alpha 1aadrenoceptor-selective antagonist: Characterization using recombinant human alpha 1-adrenoceptors and native tissues
-
Shibata K, Foglar R, Horie K, et al. KMD -3213, a novel, potent, alpha 1aadrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 1995;48: 250-8.
-
(1995)
Mol Pharmacol
, vol.48
, pp. 250-258
-
-
Shibata, K.1
Foglar, R.2
Horie, K.3
-
8
-
-
0036016946
-
α-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia
-
Thiyagarajan M. α-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia. Pharmacology 2002;65:119-28.
-
(2002)
Pharmacology
, vol.65
, pp. 119-128
-
-
Thiyagarajan, M.1
-
9
-
-
76149102783
-
-
Product information. Rapaflo (silodosin). Corona, CA: Watson Pharmaceuticals, Inc., October 2008.
-
Product information. Rapaflo (silodosin). Corona, CA: Watson Pharmaceuticals, Inc., October 2008.
-
-
-
-
10
-
-
33749572713
-
-
1A-adrenoreceptorselective antagonist for treating benign prostatic hyperplasia: results of a Phase III randomized, placebo controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24. DOI 10.1111/j.1464-410X.2006.06448.x
-
1A-adrenoreceptorselective antagonist for treating benign prostatic hyperplasia: results of a Phase III randomized, placebo controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24. DOI 10.1111/j.1464-410X.2006.06448.x
-
-
-
-
11
-
-
54849405344
-
Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
-
DOI 10.1111/j.1442-2042.2008.02154.x
-
Takao T, Tsujimura A, Kiuchi H, et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol 2008;15:992-6. DOI 10.1111/j.1442-2042.2008.02154.x
-
(2008)
Int J Urol
, vol.15
, pp. 992-996
-
-
Takao, T.1
Tsujimura, A.2
Kiuchi, H.3
-
12
-
-
67349102059
-
-
Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634-40. Epub 16 Apr 2009. DOI 10.1016/j.juro.2009.02.034
-
Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634-40. Epub 16 Apr 2009. DOI 10.1016/j.juro.2009.02.034
-
-
-
-
13
-
-
39549086056
-
-
1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2007;16:1955-64. DOI 10.1517/13543784.16.12.1955
-
1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2007;16:1955-64. DOI 10.1517/13543784.16.12.1955
-
-
-
-
14
-
-
33751019990
-
1A-adrenoceptor antagonist silodosin (KMD -3213), a drug for the treatment of voiding dysfunction
-
1A-adrenoceptor antagonist silodosin (KMD -3213), a drug for the treatment of voiding dysfunction. Arzneimittelforschung 2006;56:682-7.
-
(2006)
Arzneimittelforschung
, vol.56
, pp. 682-687
-
-
Tatemichi, S.1
Kiguchi, S.2
Kobayashi, M.3
-
15
-
-
54049121803
-
Ejaculatory dysfunction caused by the new alpha 1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography
-
DOI 10.1111/j.1442-2042.2008.02136.x
-
Nagai A, Hara R, Yokoyama T, Jo Y, Fujii T, Miyaji Y. Ejaculatory dysfunction caused by the new alpha 1-blocker silodosin: a preliminary study to analyze human ejaculation using color Doppler ultrasonography. Int J Urol 2008;15:915-8. DOI 10.1111/j.1442-2042.2008.02136.x
-
(2008)
Int J Urol
, vol.15
, pp. 915-918
-
-
Nagai, A.1
Hara, R.2
Yokoyama, T.3
Jo, Y.4
Fujii, T.5
Miyaji, Y.6
-
16
-
-
51349132022
-
Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective α1A-blocker in normal volunteers
-
Epub 9 Apr, DOI 10.1111/j.1743-6109.2008.00779.x
-
Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective α1A-blocker in normal volunteers. J Sex Med 2008;5:2185-90. Epub 9 Apr 2007. DOI 10.1111/j.1743-6109.2008.00779.x
-
(2007)
J Sex Med 2008
, vol.5
, pp. 2185-2190
-
-
Kobayashi, K.1
Masumori, N.2
Hisasue, S.3
-
17
-
-
19344367714
-
Intraoperative floppy iris syndrome associated with tamsulosin
-
DOI 10.1016/j.jcrs.2005.02.027
-
Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31:664-73. DOI 10.1016/j.jcrs.2005.02.027
-
(2005)
J Cataract Refract Surg
, vol.31
, pp. 664-673
-
-
Chang, D.F.1
Campbell, J.R.2
-
19
-
-
0033927006
-
1-adenoreceptor antagonist, in human prostate and vasculature
-
DOI 10.1016/S0022-5347(05)67426-5
-
1-adenoreceptor antagonist, in human prostate and vasculature. J Urol 2000;164:578-83. DOI 10.1016/S0022-5347(05)67426-5
-
(2000)
J Urol
, vol.164
, pp. 578-583
-
-
Murata, S.1
Taniguchi, T.2
Takahashi, M.3
Okada, K.4
Akiyama, K.5
Muramatsu, I.6
-
20
-
-
0032991607
-
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
-
Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
-
(1999)
Eur Urol
, vol.36
, pp. 1-13
-
-
Djavan, B.1
Marberger, M.2
-
21
-
-
0037347577
-
Effect of terazosin on clinical benign prostatic hyperplasia in older adults
-
Mudiyala R, Ahmed A. Effect of terazosin on clinical benign prostatic hyperplasia in older adults. J Am Geriatr Soc 2003;51:424-6.
-
(2003)
J Am Geriatr Soc
, vol.51
, pp. 424-426
-
-
Mudiyala, R.1
Ahmed, A.2
-
22
-
-
11844264906
-
Role of the newer alpha1-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia - related lower urinary tract symptoms
-
DOI 10.1016/j.clinthera.2004.11.006
-
Lowe FC. Role of the newer alpha1-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia - related lower urinary tract symptoms. Clin Ther 2004;26:1701-13. DOI 10.1016/j.clinthera.2004.11.006
-
(2004)
Clin Ther
, vol.26
, pp. 1701-1713
-
-
Lowe, F.C.1
-
23
-
-
10644274279
-
State of the art on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
-
DOI 10.1016/j.urology.2004.07.031
-
Djavan B, Chapple C, Milani S, et al. State of the art on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081-8. DOI 10.1016/j.urology.2004.07.031
-
(2004)
Urology
, vol.64
, pp. 1081-1088
-
-
Djavan, B.1
Chapple, C.2
Milani, S.3
-
24
-
-
84868172448
-
-
accessed 2010 Jan 20
-
Drugstore.com. http://drugstore.com (accessed 2010 Jan 20).
-
-
-
-
25
-
-
0031774517
-
A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing
-
DOI 10.1159/000019639
-
de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998;33:481-8. DOI 10.1159/000019639
-
(1998)
Eur Urol
, vol.33
, pp. 481-488
-
-
de Mey, C.1
Michel, M.C.2
McEwen, J.3
Moreland, T.4
-
26
-
-
51349088548
-
A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia
-
Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547-59.
-
(2008)
Int J Clin Pract
, vol.62
, pp. 1547-1559
-
-
Nickel, J.C.1
Sander, S.2
Moon, T.D.3
-
27
-
-
34249977256
-
Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: A randomized, placebo-controlled trial
-
Resnick MI, Roehrborn CG. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. Prostate Cancer Prostatic Dis 2007;10:155-9.
-
(2007)
Prostate Cancer Prostatic Dis
, vol.10
, pp. 155-159
-
-
Resnick, M.I.1
Roehrborn, C.G.2
-
28
-
-
0032100513
-
Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group
-
DOI 10.1016/S0090-4295(98)00126-5
-
Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900. DOI 10.1016/S0090-4295(98)00126-5
-
(1998)
Urology
, vol.51
, pp. 892-900
-
-
Lepor, H.1
-
29
-
-
33644827913
-
ALF-ONE Study Group. Long-term efficacy and safety of alfuzosin 10 mg once daily: A 2-year experience in 'real-life' practice
-
DOI 10.1111/j.1464-410X.2005.05962. x
-
Elhilali M, Emberton M, Matzkin H, et al.; ALF-ONE Study Group. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice. BJU Int 2006;97:513-9. DOI 10.1111/j.1464-410X.2005.05962. x
-
(2006)
BJU Int
, vol.97
, pp. 513-519
-
-
Elhilali, M.1
Emberton, M.2
Matzkin, H.3
-
30
-
-
8544265325
-
Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia
-
DOI 10.1111/j.1442-2042.2004.00913.x
-
Ichioka K, Ohara H, Terada N, et al. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. Int J Urol 2004;11:870-5. DOI 10.1111/j.1442-2042.2004.00913.x
-
(2004)
Int J Urol
, vol.11
, pp. 870-875
-
-
Ichioka, K.1
Ohara, H.2
Terada, N.3
-
31
-
-
4644351244
-
Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): First-year follow-up report
-
Palacio A, Hernández C, Marqués A, Prats J, Espinosa FJ. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report. Arch Esp Urol 2004;57:451-60.
-
(2004)
Arch Esp Urol
, vol.57
, pp. 451-460
-
-
Palacio, A.1
Hernández, C.2
Marqués, A.3
Prats, J.4
Espinosa, F.J.5
-
32
-
-
10344223529
-
Intermittent tamsulosin therapy in men with lower urinary tract symptoms
-
Yanardag H, Goktas S, Kibar Y, Kilic S, Erduran D. Intermittent tamsulosin therapy in men with lower urinary tract symptoms. J Urol 2005;173:155-7.
-
(2005)
J Urol
, vol.173
, pp. 155-157
-
-
Yanardag, H.1
Goktas, S.2
Kibar, Y.3
Kilic, S.4
Erduran, D.5
-
33
-
-
38849201263
-
-
Roehrborn CG, Siami P, Barkin J, et al.; CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616-21. Epub 21 Dec 2007. DOI 10.1016/j.juro.2007.09.084
-
Roehrborn CG, Siami P, Barkin J, et al.; CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616-21. Epub 21 Dec 2007. DOI 10.1016/j.juro.2007.09.084
-
-
-
-
34
-
-
62149096763
-
-
Barkin J, Roehrborn CG, Siami P, et al.; CombAT Study Group. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009;103:919-26. Epub 23 Feb 2009. DOI 10.1111/j.1464-410X.2009.08196.x
-
Barkin J, Roehrborn CG, Siami P, et al.; CombAT Study Group. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009;103:919-26. Epub 23 Feb 2009. DOI 10.1111/j.1464-410X.2009.08196.x
-
-
-
-
35
-
-
0347882750
-
Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
-
DOI 10.1056/NEJMoa030656
-
McConnell JD, Roehrborn CG, Bautista OM, et al.; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98. DOI 10.1056/NEJMoa030656
-
(2003)
N Engl J Med
, vol.349
, pp. 2387-2398
-
-
McConnell, J.D.1
Roehrborn, C.G.2
Bautista, O.M.3
|